Mylan (MYL): Increased Pricing Scrutiny Poses Sentiment Risk - Wells Fargo
- Noble Energy (NBL) to Acquire Clayton Williams Energy (CWEI) for $2.7B in Cash and Stock
- Nasdaq hits record; bank earnings validate Wall St. rally
- UnitedHealth Group (UNH) Tops Q4 EPS by 4c; Affirms Outlook
- Intrawest Resorts (SNOW) Exploring a Possible Sale - Reuters
- Alibaba (BABA) Has No Plans to Acquire Rest of Groupon (GRPN) - Source
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Wells Fargo analyst, David Maris, reiterated his Market Perform rating on shares of Mylan (NASDAQ: MYL) and noted that Mylan is facing further scrutiny by the press, consumers, and legislators regarding price increases on EpiPen. He believes that this issue has the potential to further pressure Mylan’s share price and "investors should be very sensitive to the investment sentiment risk".
Sen. Blumenthal (D-CT) criticized Mylan and called for the FTC and the Judiciary Antitrust Subcommittee to investigate. Senator Grassley, an Iowa Republican and Chairman of the Senate Committee on the Judiciary, sent a letter to Mylan’s CEO explaining that the “substantial price increase has caused significant concern among patients” and asked Mylan to respond to questions about EpiPen pricing. This follows Sen. Amy Klobuchar (D-MN), who over the weekend called on the FTC to investigate.
Shares of Mylan closed at $45.62 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wells Fargo (WFC) Posts Q4 EPS of $0.96, Sales Miss
- Valeant (VRX) Had 95 New Price Increases, Wells Fargo's Maris Notes
- Weekly jobless claims rise; import prices push higher
Create E-mail Alert Related CategoriesAnalyst Comments, Litigation
Related EntitiesRaising Prices, Wells Fargo, David Maris
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!